ReviewClinical advances in hematology & oncology : H&O2018
The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
Review in Clinical advances in hematology & oncology : H&O, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.Blood advances · 2022Trial
- Genome-Wide Integration Site Profiling of Multi-Component CAR T-Cell Engineering Systems with ADA1/CD26 Co-Transduction.Biomedicines · 2026Article
- In vivo CAR-T therapy: from molecular design to precision delivery.Journal of nanobiotechnology · 2026Review
- TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.Molecular cancer · 2022Article
- Challenges of CRISPR-Based Gene Editing in Primary T Cells.International journal of molecular sciences · 2022Review
- Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management.Diseases (Basel, Switzerland) · 2021Review
- The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.Transplantation and cellular therapy · 2021Article
- CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells.Nature communications · 2021Article
- A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.Frontiers in immunology · 2021Review
- Review
- Management of nephrotoxicity of chemotherapy and targeted agents: 2020.American journal of cancer research · 2020Review
- Role of immune cells in the removal of deleterious senescent cells.Immunity & ageing : I & A · 2020Review
- CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.Leukemia · 2019Review
- The Regenerative Horizon: Opportunities for Nursing Research and Practice.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2019Article
- Expression and clinical significance of neuropilin-1 in Epstein-Barr virus-associated lymphomas.Cancer biomarkers : section A of Disease markers · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected median survival of 6.3 months. In recent years, T-cell immunotherapy has demonstrated a remarkable capacity to induce complete and durable clinical responses in patients with chemotherapy-refractory lymphoma. A major contributor to the success of immunotherapy has been the advent of genetic engineering technologies that introduce a chimeric antigen receptor (CAR) into T cells to focus their killing activity on tumor cells. The adoptive transfer of autologous CAR T-cell products specific for the pan-B-cell antigen CD19 have now received approval from the US Food and Drug Administration (FDA) for the treatment of relapsed or chemotherapy-resistant B-cell non-Hodgkin lymphoma. This review is designed to showcase the clinical efficacy and unique toxicities of individually developed CAR T-cell products for the treatment of lymphomas and their evolution from the laboratory bench to commercialization.
Indexed as
Identifiers
29851933PMC6469642W2810990597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.